Core Viewpoint - The company has released its 2025 performance forecast, projecting revenue of 45.46 billion yuan (+15.8%) and a net profit attributable to shareholders of 19.15 billion yuan (+102.7%), indicating better-than-expected performance [1] Revenue and Profit Forecast - For 2025, the company expects revenue of 45.46 billion yuan, with a 15.8% year-on-year growth, and a net profit of 19.15 billion yuan, reflecting a 102.7% increase [2] - The projected revenue for 2026 and 2027 is 51.55 billion yuan (+13.4%) and 58.82 billion yuan (+14.1%), respectively [2] Business Growth and Performance - The growth rate of the continuing operations revenue is forecasted at 21.4%, exceeding previous guidance of 17-18% [1] - The company anticipates that the Chemistry business will maintain rapid growth, driven by TIDES and other business segments [1] Quarterly Performance Insights - In Q4 2025, the company expects revenue of 12.6 billion yuan (+9.2%) and a net profit of 7.08 billion yuan (+142.5%) [1] - The Non-IFRS net profit margin for Q4 2025 is projected to be 35.1%, showing stability compared to Q3 2025 and significant improvement from Q4 2024 [1] Future Profitability Potential - The company expects to generate approximately 4.16 billion yuan from the sale of equity interests and 1.43 billion yuan from the sale of clinical CRO and SMO businesses in 2025 [1] - The profitability potential for 2026 remains promising due to anticipated large orders and a stable recovery in overseas demand [1]

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [8][14]. Core Insights - WuXi AppTec's revenue for 2025 is projected to be 45.46 billion yuan, representing a year-on-year growth of 15.8%. The net profit attributable to shareholders is expected to reach 19.15 billion yuan, a significant increase of 102.7% [5][8]. - The company's continuous operating business revenue growth exceeded expectations, with a 21.4% increase compared to previous guidance of 17-18% [6]. - The fourth quarter of 2025 showed a revenue of 12.6 billion yuan, reflecting a 9.2% quarter-on-quarter growth, and a net profit of 7.08 billion yuan, which is a 142.5% increase year-on-year [5][6]. Financial Performance Summary - For 2025, the company reported a total revenue of 45.46 billion yuan, with a continuous operating business revenue growth of 21.4% [5][6]. - The fourth quarter of 2025 saw a stable net profit margin of 35.1%, slightly lower than the previous quarter but significantly higher than the same quarter last year [7]. - The projected revenues for 2025, 2026, and 2027 are 45.46 billion yuan, 51.55 billion yuan, and 58.82 billion yuan, respectively, with corresponding net profits of 19.15 billion yuan, 16.73 billion yuan, and 19.32 billion yuan [8][10].

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [8]. Core Insights - WuXi AppTec's revenue for 2025 is projected at 45.46 billion yuan, representing a year-on-year growth of 15.8%. The net profit attributable to shareholders is expected to reach 19.15 billion yuan, a significant increase of 102.7% [5][8]. - The company's core business growth exceeded expectations, with a 21.4% increase in revenue from continuing operations, surpassing previous guidance of 17-18% [6]. - The fourth quarter of 2025 showed a revenue of 12.6 billion yuan, reflecting a 9.2% quarter-on-quarter growth, and a net profit of 7.08 billion yuan, marking a 142.5% increase year-on-year [5][6]. Financial Performance Summary - For 2025, WuXi AppTec's revenue is expected to be 454.6 billion yuan, with a net profit of 191.5 billion yuan. The projections for 2026 and 2027 are 515.5 billion yuan and 588.2 billion yuan in revenue, respectively [8][10]. - The company's Non-IFRS net profit for 2025 is forecasted at 149.6 billion yuan, a 41.3% increase compared to the previous year [5]. - The report highlights a stable Non-IFRS net profit margin of 35.1% in Q4 2025, with expectations for continued improvement in profitability in 2026 due to strong demand in the Chemistry business [7][8]. Earnings Forecast and Valuation - The earnings per share (EPS) for 2025 is projected at 6.42 yuan, with a price-to-earnings (P/E) ratio of 16.3 for the same year [10][11]. - The report anticipates a gradual increase in profitability, with net profit margins expected to improve from 42.1% in 2025 to 32.9% in 2027 [11][13]. - The company's asset-liability ratio is projected to decrease from 26.4% in 2025 to 20.5% in 2026, indicating improved financial stability [11][13].

Core Viewpoint - In 2024, the company reported a revenue of 39.241 billion yuan (-2.73%) and a net profit attributable to shareholders of 9.450 billion yuan (-1.63%) [1] - Excluding COVID-19 commercialization projects, revenue growth was 5.2%, with an adjusted Non-IFRS net profit margin reaching a historical high of 27.0% [2] Financial Performance - For 2024, WuXi Chemistry achieved a revenue of 29.05 billion yuan, with a year-on-year growth of 11.2% after excluding COVID-19 projects, and an adjusted Non-IFRS gross margin of 46.4% (+1.2 percentage points) [2] - The small molecule D&M business generated a revenue of 17.87 billion yuan, with a year-on-year growth of 6.4% after excluding COVID-19 projects [2] - TIDES business revenue was 5.8 billion yuan (+70.1%), with an increase in peptide solid-phase synthesis reactor volume to 41,000L, expected to exceed 100,000L by the end of 2025 [2] - WuXi Testing business reported a revenue of 5.67 billion yuan (-4.8%) and an adjusted Non-IFRS gross margin of 33.3% (-5.9 percentage points) [2] - Laboratory analysis and testing revenue was 3.86 billion yuan (-8.0%), while clinical CRO & SMO business revenue was 1.81 billion yuan (+2.8%), with SMO revenue growing by 15.4% [2] Order Backlog and Capacity Expansion - As of the end of 2024, the company had a backlog of 49.31 billion yuan (+47.0%), compared to 43.82 billion yuan (+35.2%) at the end of September 2024, indicating strong growth in backlog [4] - The company is advancing the construction of its Middleton facility in the U.S., expected to be operational by the end of 2026, and has commenced construction of a new R&D and production base in Singapore, with phase one expected to be operational by 2027 [4] - Capital expenditure is projected to reach 7-8 billion yuan in 2025, up from 4.003 billion yuan in 2024 [4] Future Outlook - The company expects to return to double-digit revenue growth in 2025, with a projected year-on-year growth of 10%-15%, reaching a total revenue of 41.5-43 billion yuan [4] - With the gradual release of new capacity, operational efficiency is expected to improve, and the adjusted Non-IFRS net profit margin is anticipated to further increase [4] Profit Forecast and Investment Recommendation - Revenue forecasts for 2025, 2026, and 2027 are 42.706 billion yuan, 48.355 billion yuan, and 55.076 billion yuan, representing year-on-year growth of 8.8%, 13.2%, and 13.9% respectively [5] - Net profit attributable to shareholders is projected to be 10.861 billion yuan, 12.293 billion yuan, and 14.122 billion yuan for the same years, with growth rates of 14.9%, 13.2%, and 14.9% respectively [5] - The company is rated as a "buy" due to its leading position in integrated drug development services and the potential for recovery in its core Chemistry business [5]